SCHEMBL4923624

SCHEMBL4923624

Cc1nccn1CC(N)c1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.49
MAPT P10636 1/20 0.49
AGER Q15109 1/20 0.49
P2RX7 Q99572 1/20 0.48
KMT2A Q03164 4/20 0.46
MEN1 O00255 3/20 0.46
GRIN2D O15399 1/20 0.42
GRIN3B O60391 1/20 0.42
GRIN1 Q05586 1/20 0.42
GRIN2A Q12879 1/20 0.42
GRIN2B Q13224 1/20 0.42
GRIN2C Q14957 1/20 0.42
GRIN3A Q8TCU5 1/20 0.42
POLB P06746 1/20 0.41
SCN4A P35499 3/20 0.41
HPGD P15428 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19882796 0.75 KMT2A (0.48) ALDH1A1MAPTAGERKMT2AMEN1
SCHEMBL10657370 0.75 ALDH1A1 (0.44) ALDH1A1MAPTAGERP2RX7KMT2A
SCHEMBL179780 0.71 KMT2A (0.52) ALDH1A1MAPTAGERKMT2AMEN1
SCHEMBL6213236 0.71 KCNH2 (0.47) KMT2AMEN1HPGD
SCHEMBL24982894 0.71 MEN1 (0.59) ALDH1A1MAPTAGERKMT2AMEN1
SCHEMBL81625 0.70 LMNA (0.63) ALDH1A1KMT2AMEN1POLB
Benzene SCHEMBL27902631 0.70 LMNA (0.63) ALDH1A1KMT2AMEN1POLB
SCHEMBL17789537 0.70 P2RX7 (0.50) ALDH1A1MAPTAGERP2RX7KMT2A
SCHEMBL258791 0.70 MEN1 (0.76) ALDH1A1MAPTAGERKMT2AMEN1
Bromide SCHEMBL31469205 0.69 LMNA (0.61) ALDH1A1KMT2AMEN1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080306055-A1 Heterocyclic Mchr1 Antagonists And Their Use In Therapy ASTRAZENECA AB (SE) 2008-12-11 US disclosed
EP-1831194-A1 HETEROCYCLIC MCHr1 ANTAGONISTS AND THEIR USE IN THERAPY AstraZeneca AB (SE) 2007-09-12 EP disclosed
WO-2006068594-A1 HETEROCYCLIC MCHr1 ANTAGONISTS AND THEIR USE IN THERAPY ASTRAZENECA AB (SE) 2006-06-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306055-A1 Heterocyclic Mchr1 Antagonists And Their Use In Therapy MCHR1, MCHR2, MC1R ALDH1A1 2408/4885MAPT 212/4885AGER 459/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.